Aug 11, 2023
January 26, 2025
This week’s newsletter included:
-
2023 MDMA Medical Technology Executive Forum
-
BYU Hosts Industry at Networking Luncheon
-
DARPA Meets with Utah Life Sciences Leaders
-
Myriad Genetics and Intermountain Health Participate in a National Clinical Trial to Advance Cancer Treatment
-
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment
-
Bloom Surgical Gets NSF Grant & Applauds Ecosystem in Article by GOEO
-
Ogden Thermo Fisher Plant Idled
-
Utah Business Announces the 2023 HR Achievement Awards
-
Utah Business Announces Healthcare Heroes 2023 Nominations Now Open
-
Utah Business Best Companies to Work For
-
Recursion Bridges the Protein and Chemical Space
-
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
-
Sera Prognostics Announces Second Quarter Financial Results
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
